Trials / Conditions / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma

Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma

24 registered clinical trials studyying Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma.

Status	Trial	Sponsor	Phase
Completed	Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphom NCT02213913	University of Chicago	Phase 1 / Phase 2
Completed	Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Ce NCT01959477	Case Comprehensive Cancer Center	EARLY_Phase 1
Completed	Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hemato NCT01789255	National Cancer Institute (NCI)	Phase 2
Terminated	Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas NCT01805037	Northwestern University	Phase 1 / Phase 2
Withdrawn	Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant NCT01558778	Roswell Park Cancer Institute	N/A
Completed	Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple NCT02037256	Barbara Ann Karmanos Cancer Institute	N/A
Completed	Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies NCT01273766	Wake Forest University Health Sciences	Phase 2
Active Not Recruiting	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562	City of Hope Medical Center	—
Completed	Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Tran NCT01233921	Martin, Paul	N/A
Terminated	Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload NCT01159067	City of Hope Medical Center	Phase 2
Terminated	Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Bloo NCT01076270	Fred Hutchinson Cancer Center	N/A
Terminated	Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma NCT01045928	Case Comprehensive Cancer Center	Phase 1
Terminated	Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer NCT01044745	University of Nebraska	Phase 2
Completed	Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be NCT00891072	National Cancer Institute (NCI)	Phase 1
Completed	Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With NCT00856388	Roswell Park Cancer Institute	N/A
Completed	Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant NCT00795769	Fred Hutchinson Cancer Center	Phase 2
Completed	Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors NCT00799461	Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium	Phase 3
Completed	Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem NCT00489203	Fred Hutchinson Cancer Center	Phase 2
Completed	Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem NCT00408681	Fred Hutchinson Cancer Center	N/A
Completed	A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Bloo NCT00343798	Fred Hutchinson Cancer Center	Phase 1
Completed	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone To NCT00089011	Fred Hutchinson Cancer Center	Phase 2
Completed	Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Mali NCT00078858	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Completed	Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer NCT00010192	National Cancer Institute (NCI)	Phase 1
Completed	Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenola NCT00112593	Fred Hutchinson Cancer Center	N/A